Genentech Gains PARP Inhibitor Through Inotek Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
The lead product, INO-1001, is in Phase Ib for malignant melanoma.
You may also be interested in...
Genentech Ends PARP Inhibitor Collaboration With Inotek
Inotek focuses on two clinical candidates and consolidating operations.
Genentech Ends PARP Inhibitor Collaboration With Inotek
Inotek focuses on two clinical candidates and consolidating operations.
Genentech Acquires Preclinical Cardiovascular Antibody In Nearly $200 Million Deal
Firm will make $15 million up-front payment to BioInvent for North American rights to BI-204.